368 related articles for article (PubMed ID: 12816688)
1. [Benign ovarian tumor with ascites and high serum levels of CA125: report of 3 cases].
Li HJ; Shen K; Lang JH; Wu M; Huang HF; Pan LY
Zhonghua Fu Chan Ke Za Zhi; 2003 Mar; 38(3):147-9. PubMed ID: 12816688
[TBL] [Abstract][Full Text] [Related]
2. Pseudo-Meigs syndrome and elevated CA125 associated with struma ovarii.
Loizzi V; Cormio G; Resta L; Fattizzi N; Vicino M; Selvaggi L
Gynecol Oncol; 2005 Apr; 97(1):282-4. PubMed ID: 15790478
[TBL] [Abstract][Full Text] [Related]
3. Coexistence of struma ovarii with marked ascites and elevated CA-125 levels: case report and literature review.
Mui MP; Tam KF; Tam FK; Ngan HY
Arch Gynecol Obstet; 2009 May; 279(5):753-7. PubMed ID: 18807056
[TBL] [Abstract][Full Text] [Related]
4. Cystic struma ovarii presenting with ascites and an elevated CA-125 level. A case report.
Bokhari A; Rosenfeld GS; Cracchiolo B; Heller DS
J Reprod Med; 2003 Jan; 48(1):52-6. PubMed ID: 12611097
[TBL] [Abstract][Full Text] [Related]
5. [Clinical analysis of benign pelvic mass with high serum levels of CA(125)].
Zhang X; Wu LY; Li XJ; Li HJ; Zhang R; Liu LY
Zhonghua Fu Chan Ke Za Zhi; 2005 Mar; 40(3):178-82. PubMed ID: 15840313
[TBL] [Abstract][Full Text] [Related]
6. Serum C-reactive protein in the differential diagnosis of ovarian masses.
Hefler-Frischmuth K; Hefler LA; Heinze G; Paseka V; Grimm C; Tempfer CB
Eur J Obstet Gynecol Reprod Biol; 2009 Nov; 147(1):65-8. PubMed ID: 19619929
[TBL] [Abstract][Full Text] [Related]
7. Comparative analysis of CA125, tissue polypeptide specific antigen, and soluble interleukin-2 receptor alpha levels in sera, cyst, and ascitic fluids from patients with ovarian carcinoma.
Sedlaczek P; Frydecka I; Gabryś M; Van Dalen A; Einarsson R; Harłozińska A
Cancer; 2002 Nov; 95(9):1886-93. PubMed ID: 12404282
[TBL] [Abstract][Full Text] [Related]
8. Benign ovarian fibroma associated with free peritoneal fluid and elevated serum CA 125 levels.
Spinelli C; Gadducci A; Bonadio AG; Berti P; Miccoli P
Minerva Ginecol; 1999 Oct; 51(10):403-7. PubMed ID: 10638167
[TBL] [Abstract][Full Text] [Related]
9. [Cystic struma ovarii, a rare form of ovarian tumor--case report, and review of the literature].
Ostör G; Tóth I; Hrubyné Tóth Z; Bazsa S
Orv Hetil; 2007 Dec; 148(48):2285-7. PubMed ID: 18039620
[TBL] [Abstract][Full Text] [Related]
10. TPS and CA 125 levels in serum, cyst fluid and ascites of patients with epithelial ovarian neoplasms.
Harłozinska A; Sedlaczek P; Van Dalen A; Rozdolski K; Einarsson R
Anticancer Res; 1997; 17(6D):4473-8. PubMed ID: 9494553
[TBL] [Abstract][Full Text] [Related]
11. Significance of some tumor markers in differential diagnosis of ovarian tumor.
Zakrzewska I; Borawska R; Poznański J; Maćkowiak B
Rocz Akad Med Bialymst; 1999; 44():235-43. PubMed ID: 10697438
[TBL] [Abstract][Full Text] [Related]
12. Bilateral ovarian fibromatosis presenting with ascites and hirsutism.
Onderoglu LS; Gültekin M; Dursun P; Karcaaltincaba M; Usubutun A; Akata D; Ayhan A
Gynecol Oncol; 2004 Jul; 94(1):223-5. PubMed ID: 15262147
[TBL] [Abstract][Full Text] [Related]
13. High levels of CA125 (over 1,000 IU/ml) in patients with gynecologic disease and no malignant conditions: three cases and literature review.
Ghaemmaghami F; Karimi Zarchi M; Hamedi B
Arch Gynecol Obstet; 2007 Nov; 276(5):559-61. PubMed ID: 17497163
[TBL] [Abstract][Full Text] [Related]
14. Preoperative serum tetranectin, CA125 and menopausal status used as single markers in screening and in a risk assessment index (RAI) in discriminating between benign and malignant ovarian tumors.
Begum FD; Høgdall E; Kjaer SK; Blaakaer J; Christensen IJ; Christensen L; Høgdall C
Gynecol Oncol; 2009 May; 113(2):221-7. PubMed ID: 19261323
[TBL] [Abstract][Full Text] [Related]
15. The chemotactic cytokine interleukin-8--a cyst fluid marker for malignant epithelial ovarian cancer?
Ivarsson K; Runesson E; Sundfeldt K; Haeger M; Hedin L; Janson PO; Brännström M
Gynecol Oncol; 1998 Dec; 71(3):420-3. PubMed ID: 9887242
[TBL] [Abstract][Full Text] [Related]
16. Elevated serum RANTES levels in patients with ovarian cancer correlate with the extent of the disorder.
Tsukishiro S; Suzumori N; Nishikawa H; Arakawa A; Suzumori K
Gynecol Oncol; 2006 Sep; 102(3):542-5. PubMed ID: 16510173
[TBL] [Abstract][Full Text] [Related]
17. [Imaging of benign ovarian tumors].
Rouanet JP; Maubon A; Juhan V; Meny R; Salanon AP; Daclin PY
J Radiol; 2000 Dec; 81(12 Suppl):1823-30. PubMed ID: 11173751
[TBL] [Abstract][Full Text] [Related]
18. Relationship of serum levels of tumor markers with tissue expression of gene products in ovarian carcinoma.
Sorak M; Arsenijević S; Lukić G; Arsenijević N; Ristić P; Pavlović S; Popović S; Baskić D
J BUON; 2007; 12(1):99-104. PubMed ID: 17436409
[TBL] [Abstract][Full Text] [Related]
19. Serum, pleural effusion, and ascites CA-125 levels in ovarian cancer and nonovarian benign and malignant diseases: a comparative study.
Topalak O; Saygili U; Soyturk M; Karaca N; Batur Y; Uslu T; Erten O
Gynecol Oncol; 2002 Apr; 85(1):108-13. PubMed ID: 11925128
[TBL] [Abstract][Full Text] [Related]
20. [Struma ovarii: a rare tumor that deserves special management. Case report and review of the literature].
Salomon LJ; Lefevre M; Cortez A; Antoine JM; Uzan S
J Gynecol Obstet Biol Reprod (Paris); 2003 Apr; 32(2):175-8. PubMed ID: 12717308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
